Sedative and Analgesic Pharmacokinetics During Pediatric ECMO

Kanecia O Zimmerman1,2, Samantha H Dallefeld3, Christoph P Hornik1,2

  • 1Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (KOZ, CPH).

Insights

Sedatives and analgesics are crucial for critically ill children on extracorporeal membrane oxygenation (ECMO). Understanding ECMO circuit effects on drug disposition is vital for safe and effective dosing in pediatric intensive care.

Area of Science:

  • Pharmacology
  • Pediatric Critical Care
  • Extracorporeal Membrane Oxygenation

Background:

  • Sedatives and analgesics are essential for managing critically ill children requiring extracorporeal membrane oxygenation (ECMO).
  • Optimizing drug dosages is critical to ensure therapeutic efficacy and minimize adverse events.
  • The ECMO circuit can significantly alter drug pharmacokinetics, necessitating specialized dosing considerations.

Purpose of the Study:

  • To review the existing literature on the impact of the ECMO circuit on sedative and analgesic disposition in pediatric patients.
  • To provide evidence-based dosing guidance for managing sedation and analgesia in children undergoing ECMO therapy.

Main Methods:

  • Comprehensive review of in vitro studies examining drug-circuit interactions.
  • Analysis of in vivo pediatric data on sedative and analgesic pharmacokinetics during ECMO.
  • Synthesis of findings to inform clinical practice.

Main Results:

  • The ECMO circuit can influence drug metabolism, clearance, and distribution, affecting drug concentrations.
  • Variability in drug disposition is observed, influenced by circuit characteristics and patient factors.
  • Specific drug interactions with ECMO components require careful consideration for dose adjustments.

Conclusions:

  • Accurate dosing of sedatives and analgesics in pediatric ECMO patients requires a thorough understanding of drug-circuit interactions.
  • The reviewed literature supports the need for tailored dosing strategies to optimize patient outcomes.
  • Further research is warranted to refine dosing guidelines and address knowledge gaps in pediatric ECMO pharmacotherapy.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
144
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
126
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
94
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
120
Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
440
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
118